| Clinical and Regulatory | |
|---|---|
| Event Type: | Phase 2 Results |
| Timing: | H2 2016 |
| Designation(s): | Orphan Drug |
|
This event is set for a broad date range and therefore the exact timing is unknown. This adds a degree of risk.
|
|
| Disease and Treatment | |
|---|---|
| Disease: | Oncology |
| Indication: | Neuroendocrine Tumors |
| Lead Indication?: | Yes |
| Treatment Name: | CA4P (Fostrebutalin) |
|
Likelihood of event success varies depending on disease, treatment and lead indication classification.
|
|
| Company Information | |
|---|---|
| Co. Name: | OXiGENE |
| Stock Symbol: | OXGN |
| Shares Traded: | NASDAQ |
|
The OTC BB and OTC Markets have less stringent reporting and financial requirements than the NASDAQ and NYSE. This may increase the level of risk for investors. Smaller size may have an influence on likelihood of success.
|
|
| Event Status | |
|---|---|
| Event Outcome: | Ongoing |
| Event Discussion: | Forums |
| Event Announcement(s): | http://investor.mateon.com/releasedetail.cfm?releaseid=937175 |
| Partnership: | No |
|
Partnerships help smaller biotech companies finance the long approval process. Partnership also provides validation the clinical program may be a worthy investment.
|
|
Detailed Event Description from Company Announcement
Quote"The encouraging interim results seen in this Phase 2 study add to the body of evidence showing that CA4P has a positive effect in the treatment of solid tumors," said William D. Schwieterman , MD, OXiGENE's President and CEO. "We look forward to full results from this trial anticipated in the second half of 2016, as we simultaneously move to advance CA4P in later-stage trials in our core programs for ovarian cancer and glioblastoma multiforme, which will evaluate CA4P in combination with complementary, approved anti-angiogenic agents."